We Are One Seven LLC raised its holdings in shares of Icon Plc (NASDAQ:ICLR) by 4.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,733 shares of the medical research company’s stock after purchasing an additional 150 shares during the quarter. We Are One Seven LLC’s holdings in Icon were worth $550,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in ICLR. SRS Capital Advisors Inc. purchased a new position in shares of Icon during the second quarter valued at $47,000. UBS Asset Management Americas Inc. increased its stake in shares of Icon by 30.9% during the second quarter. UBS Asset Management Americas Inc. now owns 326 shares of the medical research company’s stock valued at $50,000 after buying an additional 77 shares during the period. Coastal Capital Group Inc. purchased a new position in shares of Icon during the second quarter valued at $78,000. Steward Partners Investment Advisory LLC purchased a new position in shares of Icon during the second quarter valued at $172,000. Finally, DekaBank Deutsche Girozentrale increased its stake in shares of Icon by 72.7% during the second quarter. DekaBank Deutsche Girozentrale now owns 1,328 shares of the medical research company’s stock valued at $201,000 after buying an additional 559 shares during the period. Institutional investors and hedge funds own 83.37% of the company’s stock.
ICLR opened at $142.18 on Friday. The business’s 50-day moving average is $151.08 and its two-hundred day moving average is $146.55. Icon Plc has a 1 year low of $118.10 and a 1 year high of $165.13. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.07 and a quick ratio of 2.07. The firm has a market capitalization of $7.93 billion, a PE ratio of 22.60, a price-to-earnings-growth ratio of 2.02 and a beta of 0.67.
Icon (NASDAQ:ICLR) last posted its earnings results on Wednesday, July 24th. The medical research company reported $1.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.01. Icon had a return on equity of 25.02% and a net margin of 13.05%. The company had revenue of $695.14 million for the quarter, compared to analyst estimates of $693.56 million. During the same quarter in the previous year, the firm earned $1.51 earnings per share. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. As a group, sell-side analysts expect that Icon Plc will post 6.88 EPS for the current year.
Several equities analysts have recently commented on ICLR shares. BidaskClub lowered Icon from a “buy” rating to a “hold” rating in a research note on Monday, September 30th. Zacks Investment Research lowered Icon from a “hold” rating to a “sell” rating in a research note on Thursday. ValuEngine lowered Icon from a “buy” rating to a “hold” rating in a research note on Wednesday, September 11th. Mizuho lifted their target price on Icon from $160.00 to $170.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, KeyCorp lifted their target price on Icon from $157.00 to $165.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $165.29.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Recommended Story: What are the reasons investors use put options?
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.